Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03345979 · ClinicalTrials.gov registry record · Phase 3
A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
NCT03345979 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 200 participants.
The verdict
NCT03345979, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
Interventions
- DRUG Paliperidone Palmitate
- COMBINATION_PRODUCT Aripiprazole Lauroxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2019-03-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03345979
The ClinicalTrials.gov registry entry for NCT03345979 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paliperidone Palmitate is the first listed.
NCT03345979 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03345979 about?
NCT03345979 is a clinical study titled "A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia". This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL.
What is the current status of trial NCT03345979?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2017-11-15. Estimated completion is 2019-03-12.
What interventions are being tested in trial NCT03345979?
The interventions under investigation include: Paliperidone Palmitate (DRUG), Aripiprazole Lauroxil (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03345979?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.